Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). (May 2021)

• Record Type: Journal Article
• Authors: Krug, David; Vonthein, Reinhard; Illen, Alicia; Olbrich, Denise; Barkhausen, Jörg; Richter, Julia; Klapper, Wolfram; Schmalz, Claudia; Rody, Achim; Maass, Nicolai; Bauerschlag, Dirk; Heßler, Nicole; König, Inke R.; Dellas, Kathrin; Dunst, Jürgen
• Is Part Of: Clinical and translational radiation oncology. Volume 28(2021)
• Page Start: 90
• Page End: 96
• Publication Date: 2021-05
• Subjects: Stereotactic body radiotherapy -- Stereotactic ablative radiotherapy -- Radiosurgery -- Metastatic breast cancer -- Quality of life -- Progression-free survival; Cancer -- Radiotherapy -- Periodicals; Oncology -- Periodicals; Cancer -- Radiotherapy; Oncology; Radiation Oncology; Neoplasms -- radiotherapy; Translational Medical Research; Periodicals; Electronic journals; Periodicals; 616.9940642
• DOI: 10.1016/j.ctro.2021.03.012
• Languages: English
• ISSNs: 2405-6308

Abstract

Highlights: Local ablative radiotherapy is associated with high rates of local control. Prognosis in oligometastatic disease may be improved by metastases-directed therapy. OLIGOMA assesses the role of radiotherapy in oligometastatic breast cancer patients. Abstract: Background: Several recent randomized therapeutic exploratory trials demonstrated improvement of progression-free survival and in some even overall survival using stereotactic body radiotherapy in patients with oligometastatic disease. However, only very few patients enrolled in these trials had breast cancer, and results from confirmatory trials are lacking. Methods/design: The OLIGOMA-trial is a randomized controlled multi-national multi-center therapeutic confirmatory trial studying the role of local ablative radiotherapy as an additive treatment in patients with oligometastatic breast cancer receiving standard systemic therapy. Patients will be randomized 1:1 to standard systemic therapy according to national guidelines with or without radiotherapy to all metastatic sites. Randomization will be stratified according to type and line of systemic therapy, which has to be determined by a multidisciplinary tumor board before enrollment. Patients with up to five metastatic lesions are eligible, including patients with up to three brain metastases (only in case of extracranial disease) and with locoregional recurrence (only in case of additional metastatic lesions). In the standard arm, palliative radiotherapy to symptomatic metastases is permitted if at least one lesion remains untreated. The co-primary endpoints are progression-free survival and quality of life. The primary hypothesis is that progression-free survival in the experimental arm will be superior to the standard arm while simultaneously demonstrating non-inferiority of quality of life at 12 weeks after randomization. Secondary endpoints are feasibility, overall survival, toxicity, quality of life and patient satisfaction. A translational sub-study with collection of ctDNA will be conducted. Discussion: The OLIGOMA-trial will provide high level evidence on the use of and benefit from local ablative radiotherapy for patients with oligometastatic breast cancer. Trial registration: The OLIGOMA-trial is registered at clinicialtrials.gov under the identification NCT04495309. The related information was first posted on July 31st 2020.